Nosocomial Pneumonia (Serratia marcescens)
Overview
Plain-Language Overview
Nosocomial pneumonia caused by Serratia marcescens is a lung infection that occurs in people who are already hospitalized, especially those on ventilators or with weakened immune systems. This infection affects the lungs, leading to symptoms like cough, fever, and difficulty breathing. The bacteria Serratia marcescens is a type of Gram-negative rod that can survive in hospital environments and resist many antibiotics. It can cause serious illness by invading the lung tissue and causing inflammation. This condition is important because it can complicate recovery from other illnesses and requires careful medical attention.
Clinical Definition
Nosocomial pneumonia (NP) due to Serratia marcescens is a hospital-acquired lower respiratory tract infection occurring at least 48 hours after admission, primarily affecting patients with risk factors such as mechanical ventilation or immunosuppression. The core pathology involves bacterial colonization and invasion of the alveoli and lung parenchyma, leading to an inflammatory response and impaired gas exchange. Serratia marcescens is a Gram-negative facultative anaerobic bacillus known for its intrinsic resistance to multiple antibiotics and ability to form biofilms, complicating treatment. This infection is clinically significant due to its association with increased morbidity, mortality, and prolonged hospital stays. It often presents with fever, purulent sputum, and new or progressive infiltrates on chest imaging. Early identification and targeted antimicrobial therapy are critical to improve outcomes.
Inciting Event
Endotracheal intubation and initiation of mechanical ventilation.
Exposure to contaminated hospital equipment or solutions colonized by Serratia marcescens.
Prior antibiotic therapy selecting for resistant Serratia strains.
Aspiration of oropharyngeal secretions containing Serratia into lower airways.
Latency Period
Typically 48 to 72 hours after intubation or hospital admission.
Onset may be delayed in immunosuppressed patients due to blunted inflammatory response.
Symptoms usually develop within the first week of ICU stay.
Diagnostic Delay
Non-specific clinical presentation overlapping with other causes of pneumonia.
Initial empiric antibiotics may mask symptoms and delay culture positivity.
Difficulty distinguishing colonization from true infection in respiratory cultures.
Lack of early radiographic changes in some cases leading to delayed imaging.
Clinical Presentation
Signs & Symptoms
Fever and chills indicating systemic infection
Productive cough with purulent sputum
Dyspnea and tachypnea reflecting impaired gas exchange
Pleuritic chest pain due to pleural inflammation
Confusion or altered mental status in elderly or severe cases
History of Present Illness
Fever and purulent sputum production developing after several days of hospitalization.
Worsening respiratory status with increased oxygen requirements or ventilator settings.
New onset or worsening cough and dyspnea in a mechanically ventilated patient.
Chest discomfort or pleuritic pain may be present but often masked by sedation.
Past Medical History
Recent hospitalization or ICU admission with invasive procedures.
Chronic lung diseases such as COPD or bronchiectasis increasing susceptibility.
Prior use of broad-spectrum antibiotics altering normal respiratory flora.
Immunosuppressive conditions or therapies impairing host defenses.
Family History
[]
Physical Exam Findings
Fever and tachypnea indicating systemic infection and respiratory distress
Crackles or rales on lung auscultation due to alveolar inflammation
Dullness to percussion over affected lung segments from consolidation
Bronchial breath sounds suggesting lung consolidation
Use of accessory muscles of respiration in severe cases
Diagnostic Workup
Diagnostic Criteria
Diagnosis requires the presence of a new or progressive pulmonary infiltrate on chest X-ray plus at least two clinical signs such as fever, leukocytosis, or purulent respiratory secretions. Microbiological confirmation is obtained by isolating Serratia marcescens from lower respiratory tract samples, such as endotracheal aspirate or bronchoalveolar lavage cultures. Quantitative cultures with significant bacterial growth support the diagnosis, especially in ventilated patients. Blood cultures may be positive in severe cases. The diagnosis excludes infections present on admission to confirm the nosocomial origin.
Pathophysiology
Key Mechanisms
Colonization of the respiratory tract by Serratia marcescens due to impaired host defenses.
Biofilm formation on endotracheal tubes or catheters facilitating persistent infection.
Production of proteases and hemolysins by Serratia marcescens causing tissue damage.
Impaired mucociliary clearance and alveolar macrophage dysfunction in hospitalized patients.
Inflammatory response leading to alveolar exudate and consolidation characteristic of pneumonia.
| Involvement | Details |
|---|---|
| Organs | Lungs are the main organs affected, with infection leading to consolidation, impaired oxygenation, and respiratory symptoms. |
Kidneys may be affected indirectly due to nephrotoxic effects of certain antibiotics used in treatment. | |
| Tissues | Alveolar tissue is the primary site of infection and inflammation in nosocomial pneumonia caused by Serratia marcescens. |
Bronchial mucosa becomes inflamed and edematous, contributing to airway obstruction and impaired gas exchange. | |
| Cells | Neutrophils are the primary immune cells recruited to the lungs to phagocytose and kill Serratia marcescens during infection. |
Alveolar macrophages initiate the innate immune response by recognizing bacterial components and releasing proinflammatory cytokines. | |
Epithelial cells of the respiratory tract act as a physical barrier and produce antimicrobial peptides to limit bacterial invasion. | |
| Chemical Mediators | Interleukin-8 (IL-8) is a key chemokine that recruits neutrophils to the site of pulmonary infection. |
Tumor necrosis factor-alpha (TNF-α) promotes inflammation and enhances the bactericidal activity of immune cells in the lungs. | |
Prostaglandins contribute to the inflammatory response and modulate vascular permeability in infected lung tissue. |
Treatments
Pharmacological Treatments
Carbapenems
- Mechanism:
Inhibit bacterial cell wall synthesis by binding penicillin-binding proteins, effective against multidrug-resistant Serratia marcescens.
- Side effects:
Seizures
Allergic reactions
Gastrointestinal upset
- Clinical role:
First-line
Third-generation cephalosporins (e.g., ceftriaxone)
- Mechanism:
Inhibit bacterial cell wall synthesis with broad-spectrum activity including Serratia marcescens.
- Side effects:
Allergic reactions
Diarrhea
Superinfection
- Clinical role:
First-line
Fluoroquinolones (e.g., ciprofloxacin)
- Mechanism:
Inhibit bacterial DNA gyrase and topoisomerase IV, effective against gram-negative pathogens including Serratia marcescens.
- Side effects:
Tendonitis
QT prolongation
Gastrointestinal upset
- Clinical role:
Second-line
Aminoglycosides (e.g., gentamicin)
- Mechanism:
Bind 30S ribosomal subunit causing misreading of mRNA and bactericidal activity against gram-negative bacteria.
- Side effects:
Nephrotoxicity
Ototoxicity
Neuromuscular blockade
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Supportive oxygen therapy to maintain adequate oxygenation in patients with respiratory compromise.
Mechanical ventilation for patients with respiratory failure or severe hypoxemia.
Chest physiotherapy to aid in secretion clearance and improve lung expansion.
Strict infection control measures including hand hygiene and isolation to prevent nosocomial spread.
Prevention
Pharmacological Prevention
Appropriate perioperative antibiotic prophylaxis in high-risk patients
Targeted antibiotic stewardship to reduce resistant Serratia marcescens strains
Selective digestive decontamination in ICU patients to prevent colonization
Non-pharmacological Prevention
Strict hand hygiene to prevent nosocomial transmission
Elevating the head of the bed to reduce aspiration risk
Early mobilization and pulmonary hygiene to prevent atelectasis
Minimizing duration of mechanical ventilation
Regular oral care to reduce oropharyngeal colonization
Outcome & Complications
Complications
Sepsis and septic shock from systemic spread
Lung abscess formation due to necrotizing infection
Empyema from pleural space infection
Acute respiratory distress syndrome (ARDS) from severe inflammation
Multiorgan failure in critically ill patients
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Nosocomial Pneumonia (Serratia marcescens) versus Pseudomonas aeruginosa Pneumonia
Nosocomial Pneumonia (Serratia marcescens) | Pseudomonas aeruginosa Pneumonia |
|---|---|
Gram-negative rod producing red pigment (prodigiosin) | Gram-negative rod with characteristic blue-green pigment and fruity odor |
Often associated with prolonged hospitalization and mechanical ventilation | Common in patients with cystic fibrosis or bronchiectasis |
Frequently resistant to multiple antibiotics including beta-lactams and aminoglycosides | Typically sensitive to antipseudomonal beta-lactams and aminoglycosides |
Nosocomial Pneumonia (Serratia marcescens) versus Klebsiella pneumoniae Pneumonia
Nosocomial Pneumonia (Serratia marcescens) | Klebsiella pneumoniae Pneumonia |
|---|---|
Patchy or diffuse infiltrates without bulging fissure | Lobar consolidation with bulging fissure sign |
Gram-negative rod with red pigment production | Encapsulated gram-negative rod with mucoid colonies |
Common in ICU patients with invasive devices | Common in alcoholics and diabetics |
Nosocomial Pneumonia (Serratia marcescens) versus Staphylococcus aureus Pneumonia
Nosocomial Pneumonia (Serratia marcescens) | Staphylococcus aureus Pneumonia |
|---|---|
Gram-negative rod | Gram-positive cocci in clusters |
Typically occurs as a late-onset nosocomial infection | Often follows influenza infection with rapid progression |
Less commonly causes abscesses; more often bronchopneumonia | Necrotizing pneumonia with abscess formation |
Nosocomial Pneumonia (Serratia marcescens) versus Acinetobacter baumannii Pneumonia
Nosocomial Pneumonia (Serratia marcescens) | Acinetobacter baumannii Pneumonia |
|---|---|
Gram-negative rod producing red pigment | Gram-negative coccobacillus, non-pigmented |
Common in prolonged hospital stays with invasive devices | Common in ventilated patients in tropical or war-zone settings |
Multidrug resistance common, often resistant to colistin as well | Often multidrug-resistant but may respond to colistin |
Nosocomial Pneumonia (Serratia marcescens) versus Legionella pneumophila Pneumonia
Nosocomial Pneumonia (Serratia marcescens) | Legionella pneumophila Pneumonia |
|---|---|
Extracellular gram-negative rod with red pigment | Intracellular gram-negative rod detected by urinary antigen test |
Hospital-acquired infection related to invasive procedures | Exposure to contaminated water sources or air conditioning systems |
Hyponatremia less common; no characteristic liver enzyme elevation | Hyponatremia and elevated liver enzymes common |